Camille Nelson Kotton MD, FIDSA, FAST is the clinical director of the Transplant Infectious Disease and Immunocompromised Host Program at the Massachusetts General Hospital, and Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts. She was chair of The Infectious Disease Community of Practice of The American Society of Transplantation (2012-2018). From 2007-2013, she was the president of The Transplant Infectious Disease Section of The Transplantation Society. Highlights of her time as president include the development of international guidelines on CMV management after solid organ transplant, published in Transplantation (2010, 2013, 2018). She is the first transplant infectious disease specialist to be a councilor of The Transplantation Society (2020). Her clinical interests include cytomegalovirus, donor-derived infections, zoonoses, and travel and tropical medicine in the transplant setting. During the COVID-19 pandemic, she managed numerous COVID-19 infected patients, developed clinical protocols for management, and reviewed hundreds of clinical charts to facilitate diagnosis. Dr. Kotton has been an advisor to a consortium of local private schools regarding safe return to school. She is the local investigator for the  “Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress”. She is a contributing author on the CID paper “COVID-19 in solid organ transplant: A multi-center cohort study”, and on the submitted dual-center manuscript, “Impact of cancer on outcomes among hospitalized COVID-19 patients”. She is a new nominee to the CDC Advisory Committee on Immunization Practices (ACIP)